CLINICAL TRIALS PROFILE FOR CABOZANTINIB S-MALATE
✉ Email this page to a colleague
All Clinical Trials for cabozantinib s-malate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01708954 ↗ | Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer | Active, not recruiting | National Cancer Institute (NCI) | Phase 2 | 2013-02-13 | This randomized phase II trial studies how well giving erlotinib hydrochloride and cabozantinib-s-malate alone or in combination works as second or third line therapy in treating patient with stage IV non-small cell lung cancer. Erlotinib hydrochloride and cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving erlotinib hydrochloride together with cabozantinib-s-malate is more effective than erlotinib hydrochloride or cabozantinib-s-malate alone in treating non-small cell lung cancer. |
| NCT01709435 ↗ | Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors | Completed | National Cancer Institute (NCI) | Phase 1 | 2012-11-14 | This phase I trial studies the side effects and best dose of cabozantinib S-malate in treating younger patients with solid tumors that have come back or no longer respond to treatment. Cabozantinib S-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. |
| NCT01716715 ↗ | Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | 2012-11-06 | This randomized phase II trial studies how well giving cabozantinib-s-malate or paclitaxel works in treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether cabozantinib-s-malate or paclitaxel is more effective at treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer. |
| NCT01811212 ↗ | Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer | Completed | Exelixis | Phase 2 | 2013-05-08 | This phase II trial studies how well cabozantinib-s-malate works in treating patients with thyroid cancer that does not respond to treatment. Cabozantinib-s-malate may stop the growth of thyroid cancer by blocking some of the enzymes needed for cell growth. Cabozantinib-s-malate may also stop the growth of thyroid cancer by blocking blood flow to the tumor. |
| NCT01811212 ↗ | Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | 2013-05-08 | This phase II trial studies how well cabozantinib-s-malate works in treating patients with thyroid cancer that does not respond to treatment. Cabozantinib-s-malate may stop the growth of thyroid cancer by blocking some of the enzymes needed for cell growth. Cabozantinib-s-malate may also stop the growth of thyroid cancer by blocking blood flow to the tumor. |
| NCT01812668 ↗ | Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer | Completed | United States Department of Defense | N/A | 2013-03-01 | This pilot clinical trial studies cabozantinib-s-malate in treating patients with hormone-resistant metastatic prostate cancer. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth |
| NCT01812668 ↗ | Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer | Completed | Barbara Ann Karmanos Cancer Institute | N/A | 2013-03-01 | This pilot clinical trial studies cabozantinib-s-malate in treating patients with hormone-resistant metastatic prostate cancer. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for cabozantinib s-malate
Condition Name
| Condition Name for cabozantinib s-malate | |
| Intervention | Trials |
| Stage IV Renal Cell Cancer AJCC v8 | 6 |
| Metastatic Renal Cell Carcinoma | 4 |
| Recurrent Malignant Solid Neoplasm | 4 |
| Recurrent Hepatocellular Carcinoma | 3 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for cabozantinib s-malate
Trials by Country
Clinical Trial Progress for cabozantinib s-malate
Clinical Trial Phase
Clinical Trial Sponsors for cabozantinib s-malate
Sponsor Name
